Idorsia Kasumi ja hinna suhe 2024

Mis teeb Idorsia?

Idorsia Ltd is a biopharmaceutical company that focuses on the discovery, development, and marketing of innovative therapies for patients. The company is headquartered in Switzerland and was founded in 2017 after being spun off from Actelion Ltd. Idorsia was formed by a team of experienced scientists and developers who are known in the industry for their skills and passion for researching new therapies. The company is divided into five main business areas: cardiovascular and respiratory, CNS, immunology, pain, and oncology. Through its research and development activities, Idorsia aims to address medical needs in various areas. The company's innovative therapy approaches have already shown promise and garnered significant attention in the industry. Idorsia receives support from investors and partners. Idorsia's business model is based on an extensive portfolio of already patented and yet-to-be-patented drugs. The company strives to continually optimize and expand its developments within the industry to ultimately treat patients worldwide with its therapies. It collaborates closely with various partners from the biotechnology, pharmaceutical, and other industries to bring products to market and translate scientific knowledge into clinical practice. In the cardiovascular and respiratory field, Idorsia focuses on developing therapies for pulmonary hypertension as well as severe, acute, and chronic cardiovascular diseases. The company's goal is to reduce interventions and interventions for the treatment of these diseases through new treatment options, thus effectively and sustainably improving patients' quality of life. In neurology, Idorsia is involved in research and development of new therapies for disorders of the central nervous system. Here, the company targets the treatment of severe conditions such as epilepsy, sleep disorders, Alzheimer's, and Parkinson's. The research and development activities are carried out in close collaboration with academic research centers and clinics and have already shown success in developing new therapies. In the field of immunology, the company focuses on the development of biological therapies to support the body's immune system in fighting tumors and other severe diseases. Idorsia also focuses on the advancement of personalized medicines tailored to individual patients. In terms of pain, the company focuses on developing therapies that can effectively reduce pain without affecting the patient's perception and quality of life. Idorsia is working on the development of treatment methods that span longer periods and thus serve as an effective alternative to conventional pain therapies. One of the main products introduced by Idorsia is the drug Daridorexant. The drug is a highly selective receptor antagonist developed for the treatment of sleep disorders and other sleep-related conditions. In addition, Idorsia is working on the development of new therapies in the neurology and cardiovascular disease fields. Overall, Idorsia is dedicated to providing patients with valuable and innovative treatment options and, thereby, improving their quality of life. The company relies on scientific research and continuous improvement of its products and services to ensure long-term success in the industry. Idorsia ist eines der beliebtesten Unternehmen auf Eulerpool.com.